Modality
Multispecific
MOA
SGLT2i
Target
CD47
Pathway
T-cell
PsoriasisFSGSSMA
Development Pipeline
Preclinical
May 2021
→ Sep 2030
PreclinicalCurrent
NCT06688248
2,485 pts·FSGS
2021-05→2030-01·Completed
NCT05500907
975 pts·FSGS
2023-12→2030-09·Recruiting
3,460 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-01-223.8y awayInterim· FSGS
2030-09-054.4y awayInterim· FSGS
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2030-01-22 · 3.8y away
FSGS
Interim
2030-09-05 · 4.4y away
FSGS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06688248 | Preclinical | FSGS | Completed | 2485 | VA |
| NCT05500907 | Preclinical | FSGS | Recruiting | 975 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |